会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
    • 吡唑衍生物,含有该吡唑衍生物的药物组合物,其医药用途及其生产用中间体
    • US07635684B2
    • 2009-12-22
    • US10525197
    • 2003-08-21
    • Nobuhiko FushimiKazuo ShimizuShigeru YonekuboHirotaka TeranishiMasaki TomaeMasayuki Isaji
    • Nobuhiko FushimiKazuo ShimizuShigeru YonekuboHirotaka TeranishiMasaki TomaeMasayuki Isaji
    • A61K31/7028A01N43/56C07H17/02C07D231/12
    • A61K38/185A61K31/00A61K31/10A61K31/205A61K31/37A61K31/4166A61K31/7056A61K31/7072A61K31/737A61K38/1858A61K38/28A61K45/06C07H17/02A61K2300/00
    • The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents —RB, —CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.
    • 本发明提供由以下通式表示的吡唑衍生物:其中R1表示H,任选取代的C 1-6烷基等; Q和T之一表示由通式表示的基团或由通式表示的基团:而另一个表示任选取代的C 1-6烷基等; R2表示H,卤素原子,OH,任意取代的C 1-6烷基等; X表示单键,O或S; Y表示任选取代的C 1-6亚烷基等; Z表示-RB,-CORC等,其中RB表示任选取代的C 1-6烷基等; 并且RC表示任选取代的C 1-6烷基等; R4代表H,任选取代的C 1-6烷基等; R3,R5和R6表示H,卤素原子等,其药学上可接受的盐或其前药,其在人SGLT1中表现出优异的抑制活性,并且可用作预防或治疗与高血糖相关的疾病的药剂,例如 糖尿病,葡萄糖耐量减低,空腹血糖受损,糖尿病并发症或肥胖症,以及与半乳糖水平升高相关的疾病,以及包含其的药物组合物,其制药用途及其生产用中间体。
    • 8. 发明授权
    • Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
    • 吡唑衍生物,含有该吡唑衍生物的药物组合物,其医药用途及其生产用中间体
    • US08324176B2
    • 2012-12-04
    • US12421236
    • 2009-04-09
    • Nobuhiko FushimiKazuo ShimizuShigeru YonekuboHirotaka TeranishiMasaki TomaeMasayuki Isaji
    • Nobuhiko FushimiKazuo ShimizuShigeru YonekuboHirotaka TeranishiMasaki TomaeMasayuki Isaji
    • A61K31/7028C07H17/02
    • A61K38/185A61K31/00A61K31/10A61K31/205A61K31/37A61K31/4166A61K31/7056A61K31/7072A61K31/737A61K38/1858A61K38/28A61K45/06C07H17/02A61K2300/00
    • The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents —RB, —CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.
    • 本发明提供由以下通式表示的吡唑衍生物:其中R1表示H,任选取代的C 1-6烷基等; Q和T之一表示由通式表示的基团或由通式表示的基团:而另一个表示任选取代的C 1-6烷基等; R2表示H,卤素原子,OH,任意取代的C 1-6烷基等; X表示单键,O或S; Y表示任选取代的C 1-6亚烷基等; Z表示-RB,-CORC等,其中RB表示任选取代的C 1-6烷基等; 并且RC表示任选取代的C 1-6烷基等; R4代表H,任选取代的C 1-6烷基等; R3,R5和R6表示H,卤素原子等,其药学上可接受的盐或其前药,其在人SGLT1中表现出优异的抑制活性,并且可用作预防或治疗与高血糖相关的疾病的药剂,例如 糖尿病,葡萄糖耐量减低,空腹血糖受损,糖尿病并发症或肥胖症,以及与半乳糖水平升高相关的疾病,以及包含其的药物组合物,其制药用途及其生产用中间体。
    • 9. 发明授权
    • Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
    • 吡唑衍生物,含有该吡唑衍生物的药物组合物,其医药用途及其生产用中间体
    • US07655632B2
    • 2010-02-02
    • US12104890
    • 2008-04-17
    • Hirotaka TeranishiNobuhiko FushimiShigeru YonekuboKazuo ShimizuToshihide ShibazakiMasayuki Isaji
    • Hirotaka TeranishiNobuhiko FushimiShigeru YonekuboKazuo ShimizuToshihide ShibazakiMasayuki Isaji
    • A01N43/04A61K31/70
    • C07H17/02
    • The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C1-6 alkylene group etc.; Z represents CO or SO2; R4 and R5 represent H, an optionally substituted C1-6 alkyl group etc.; and R3, R6 and R7 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.
    • 本发明提供由以下通式表示的吡唑衍生物:其中R1表示H,任选取代的C 1-6烷基等; Q和T之一表示由通式表示的基团或由通式表示的基团:而另一个表示任选取代的C 1-6烷基等; R2表示H,卤素原子,OH,任意取代的C 1-6烷基等; X表示单键,O或S; Y表示单键,C1-6亚烷基等; Z表示CO或SO2; R4和R5代表H,任选取代的C 1-6烷基等; R 3,R 6和R 7表示H,卤素原子等,其药学上可接受的盐或其前药,其在人SGLT1中表现出优异的抑制活性,并且可用作预防或治疗与高血糖相关的疾病 糖尿病,糖尿病并发症或肥胖症,以及包含该药物组合物的药物组合物,其药学用途及其生产用中间体。